News

Xiapex is the trade name for collagenase clostridium histolyticum (CCH) in the European Union (EU). Currently, Xiapex is approved to treat Dupuytren’s contracture in adult patients with a

The double-masked, randomized sham controlled trial is designed to evaluate the safety, tolerability and pharmacokinetics of QPI-1007 in these patients. QPI-1007 is a siRNA designed drug designed to

ADXS-cHER2 is being developed to target the Her2 receptor, which is overexpressed in certain solid-tumor cancers, including bone cancer (osteosarcoma), breast cancer, esophageal and gastric cancer. The company

Mersana’s Fleximer technology will be used in the development of ADCs for multiple undisclosed targets. The two firms will test a variety of ADCs by using Mersana’s platform

The purchase price of Dava is $575m in cash, with additional consideration of about $25m contingent on the achievement of certain sales milestones. The acquisition would improve Endo’s

The company said that the patent has broad coverage and protects development of any apoptosis-inducing ICAM-1 antibody. BioInvent chief scientific officer Björn Frendéus said the company is happy

Bristol-Myers Squibb will expand access to a broader set of clinical trial information from in-scope company-sponsored studies and enable an independent scientific review through DCRI of requests from

In June 2014, EnGeneIC completed a Phase 1 trial in recurrent glioma in Australia and now plans to submit an IND and commence the U.S. clinical program in

Bruce Burns, Senior Vice President at Windmill, said, "Our pharmacies like the fact that we bring them new innovative products of this caliber." "We have nothing else like